SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation.

导出 LinkOut

翻译打印收藏纠错

作者： Liao,Wang ^[1] ; Yinghui,Sun ^[2] ; Xijie,Liu ^[3] ; Hongjuan,Li ^[3] ; Chang,Lu ^[3] ; Ronghui,Yang ^[3] ; Chuanzhen,Yang ^[1] ; Binghui,Li ^[2]

作者单位： Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China. ^[1] Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100069, China. ^[2] Shouyao Holdings Co., Ltd, Beijing 100195, China. ^[3]

关键词 B-cell malignancies BCR signaling BTK SY-1530 irreversible inhibitor

DOI 10.20892/j.issn.2095-3941.2020.0291

PMID 34264564

发布时间 2024-02-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer biology & medicine

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation.

Cancer biology & medicine

相似文献

Cancer biology & medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation.

Cancer biology & medicine

相似文献

Cancer biology & medicine

相关期刊

检索历史清除